

1 **Documented transboundary transmission of mpox between the Central African Republic**
2 **and the Democratic Republic of the Congo**

3
4 Emmanuel Hasivirwe Vakaniaki^{1,2}, Eddy Kinganda-Lusamaki^{1,3,4}, Sydney Merritt⁵, Francois
5 Kasongo¹, Emile Malembi⁶, Lygie Lunyanga¹, Sylvie Linsuke¹, Megan Halbrook⁵, Ernest
6 Kalthan⁷, Elisabeth Pukuta¹, Adrienne Amuri Aziza¹, Jean Claude Makangara Cigolo^{1,3,8},
7 Raphael Lumembe^{1,3}, Gabriel Kabamba^{1,3}, Yvon Anta¹, Pierrot Bolunza⁹, Innocent Kanda⁹,
8 Raoul Nganzobo¹⁰, Thierry Kalonji⁶, Justus Nsio¹¹, Patricia Matoka¹¹, Dieudonné Mwamba¹²,
9 Christian Ngandu¹², Souradet Y. Shaw¹³, Robert Shongo⁶, Joule Madinga¹, Yap Boum¹⁴,
10 Laurens Liesenborghs², Eric Delaporte⁴, Ahidjo Ayouba⁴, Nicola Low^{8,15}, Steve Ahuka
11 Mundeke^{1,3}, Lisa E. Hensley¹⁶, Jean-Jacques Muyembe Tamfum^{1,3}, Emmanuel Nakoune¹⁴,
12 Martine Peeters^{4*}, Nicole A. Hoff^{5*}, Jason Kindrachuk^{17,18}, Anne W. Rimoin^{5*}, Placide Mbala-
13 Kingebeni^{1,3*}

- 14
15 1. Institut National de Recherche Biomédicale, Kinshasa, Democratic Republic of Congo
16 2. Department of Clinical Sciences, Institute of Tropical Medicine, Antwerp, Belgium
17 3. Service de Microbiologie, Département de Biologie Médicale, Cliniques Universitaires de
18 Kinshasa, Kinshasa University, Democratic Republic of Congo
19 4. TransVIHMI (Recherches Translationnelles sur le VIH et les Maladies Infectieuses
20 endémiques et émergentes), Université de Montpellier, French National Research Institute
21 for Substaminale Développement (IRD), INSERM, Montpellier, France
22 5. Department of Epidemiology, Jonathan and Karin Fielding School of Public Health,
23 University of California, Los Angeles, CA, USA
24 6. Hemorrhagic Fevers and Monkeypox Program, Ministry of Health, Democratic Republic of
25 the Congo
26 7. Ministry of Health and Populations, Bangui, Central African Republic
27 8. Graduate School for Cellular and Biomedical Sciences, University of Bern, Bern,
28 Switzerland
29 9. Provincial Health Division, South Ubangi, Democratic Republic of Congo
30 10. Mbaya Health Zone, South Ubangi, Democratic Republic of Congo
31 11. National Border Hygiene Program, Ministry of Health, Democratic Republic of Congo
32 12. National Institute of Public Health, Ministry of Health, Democratic Republic of Congo

- 33 13. Department of Community Health Sciences, Max Rady College of Medicine, University of
34 Manitoba, Winnipeg, Manitoba, Canada
- 35 14. Pasteur Institute of Bangui
- 36 15. Institute of Social and Preventive Medicine (ISPM), University of Bern, Switzerland
- 37 16. Zoonotic and Emerging Disease Research Unit, National Bio and
38 Agro-Defense Facility, USDA Agricultural Research Service (ARS), Manhattan,
39 Kansas.
- 40 17. Department of Medical Microbiology & Infectious Diseases, University of Manitoba,
41 Winnipeg, Manitoba, Canada
- 42 18. Manitoba Centre for Proteomics & Systems Biology, Department of Internal Medicine,
43 University of Manitoba, Winnipeg, Manitoba, Canada

44
45
46
47
48
49
50
51

52 ***Corresponding author:***

53 Anne Rimon, PhD, MPH
54 Professor, Department of Epidemiology, Gordon-Levin Endowed Chair in Infectious Diseases
55 and Public Health
56 UCLA Fielding School of Public Health,
57 650 Charles E. Young Dr, CHS 41-275, Los Angeles, CA 90095, USA
58 Phone: +1(310) 409-6299
59 E-mail: arimoin@ucla.edu
60 Institutional webpage: www.ucla.edu

61

62 ***Co-corresponding author:***

63 Placide Mbala-Kingebeni, MD, PhD
64 Associate Professor, School of Medicine, University of Kinshasa (UNIKIN)
65 Department of Epidemiology and Global Health; Head of Pathogen Genomics Laboratory,
66 Institute National de la Recherche Biomédicale (INRB), Kinshasa, Democratic Republic of the
67 Congo (DRC)
68 Phone: +243 822 851 584
69 E-mail: mbalaplacide@gmail.com
70 Institutional webpage: <https://inrb.net/>

71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100
101
102

ABSTRACT

Four confirmed mpox cases in South Ubangi province, Democratic Republic of the Congo, were linked to documented transboundary transmission from Central African Republic. Viral genome sequencing shows that the MPXV sequences belong to subclade Ia. This demonstrates the borderless nature of mpox and highlights the need for vigilant regional surveillance.

Keywords: mpox; Democratic Republic of the Congo; Central African Republic; surveillance; cross-border transmission; subclade Ia; MPXV

103

104

105 INTRODUCTION

106 Mpox is a zoonotic viral infectious disease first identified in humans in the Democratic Republic
107 of the Congo (DRC) in 1970 (1). Monkeypox virus (MPXV) is endemic in forested regions of
108 Central and West Africa (2), subclassified into two clades: Clade I and Clade II, where subclade
109 I1b was responsible for a global epidemic in 2022 (3). We have recommended subdivision of
110 Clade I into subclades Ia and Ib, the latter associated with sustained human-to-human
111 transmission in DRC (4). Clade I is endemic in Central Africa, particularly in the DRC and
112 infections are associated with greater disease severity than Clade II (5, 6). Zoonotic spillover has
113 been the primary driver of Clade I MPXV infections; however, sustained human-to-human
114 transmission is increasing and spread of Clade I MPXV through sexual contact has been reported
115 in multiple regions of the DRC (4, 7).

116 The DRC has faced the greatest mpox burden among endemic regions. The number of reported
117 cases has been increasing since the cessation of smallpox vaccination campaigns in 1980 (8).
118 This increase has accelerated from 2022 onwards (9), including into regions with no previously
119 reported cases (10). While cross-border travel has been demonstrated as a factor involved in
120 transmission of Clade II MPXV, less is known for Clade I cases in regional settings. Given the
121 recent geographic expansion for Clade I MPXV and increasing observation of sustained human-
122 to-human transmission, there are considerable concerns about geographic expansion of mpox
123 through cross-border transmission (10).

124 The Central African Republic (CAR) shares a >1,000-mile border with DRC. CAR has reported
125 40 confirmed mpox outbreaks (95 suspected from 2001-2021), increasing from 0-2 annually
126 from 2001-2017 to nine annually since 2018 (11). Most of these outbreaks occurred in two
127 regions along the DRC border. Here, we report suspected cross-border transmission of mpox
128 between CAR and DRC in 2023 and potential links with MPXV circulation in DRC.

129

130 THE STUDY

131 An alert for a suspected mpox case was issued by the South Ubangi Provincial Health Division,
132 DRC, in January 2023 following the death of a fisherman who presented with respiratory distress
133 and skin lesions in Mbaya Health Zone. South Ubangi Province directly borders CAR, separated

134 by the Ubangi River. The National Programme for Control of Mpox and Viral Haemorrhagic
135 Fevers (PNLMPX-VHF) and the National Institute for Biomedical Research (INRB) deployed a
136 multidisciplinary team to investigate the case with the South Ubangi Provincial Health Division.
137 As part of the investigation, the national and provincial health teams conducted supplemental
138 training sessions to raise awareness of the clinical signs and transmission modes for mpox.

139 **Figure 1** shows a documented chain of MPXV transmission from CAR to Mbaya Health Zone.
140 The index case was an adult old male resident of Bangui, CAR, who moved frequently between
141 CAR and DRC via the Ubangi River (cluster 1, case 1: C1). Following suspected exposure to
142 wildlife meat and the potential consumption of rodents in CAR in early January 2023, with
143 symptom onset began shortly after (day 0) and including fever, headache, chills, and cutaneous
144 rash. After traveling to the DRC, he was admitted to Mbaya General Reference Hospital two
145 days later, where he died on day 9 post-symptom onset after experiencing respiratory distress.
146 No samples were collected from this probable mpox case nor any information on his immune
147 status.

148 Fifteen contacts of the patient were identified in Mbaya Health Zone, including five health care
149 workers and 10 close contacts (four close friends and six family contacts). The investigation
150 revealed a cluster of three symptomatic family contacts. Two had samples taken, which were
151 positive for MPXV by PCR; the adult female partner of C1 (C2) and their child (C3). A second
152 child of C1 and C2 (C4) was treated locally for suspected mpox through traditional methods and
153 was not investigated further. No suspected mpox cases were identified among family or close
154 contacts of C1 in Bangui, CAR.

155 During the investigation, a second mpox cluster was identified, which likely originated from a
156 different source. Three suspected mpox cases were identified at the same hospital and at the
157 same time as the first cluster, with no known epidemiologic link. An adult female patient (cluster
158 2, case 1: D1) was hospitalized for nonspecific signs of mpox at the same time as C1 and
159 reported contact with a child with mpox symptoms ~28 days prior. The two additional suspected
160 cases were the child of D1 (D2), with subsequent PCR-confirmed mpox, and a contact of D2
161 (D3) who tested PCR negative. (**Figure 2**).

162 Confirmed mpox clinical symptoms among the confirmed cases included multiple pustular and
163 papular lesions (C2), disseminated pustules (C3), discreet lacrimation in the left eye and post-
164 inflammatory hyperpigmentation (D1), and hyperpigmented, disseminated macules and steep-
165 edged ulcerations (D2).

166 Subsequent viral genome sequencing was performed on three PCR-positive samples: two family
167 members in the first mpox cluster (C2 and C3) and one from the second cluster (D2) (**Figure 3**).
168 Phylogenetic analysis included 98 clade I MPXV previously published genomes. The
169 phylogenetic tree was generated by maximum likelihood using the K3Pu+F+I model (12, 13).
170 The three sequences, all clade Ia, clustered with MPXV genome sequences isolated from CAR.
171 The genetic distance between the new cases and the date between the CAR and DRC samples is
172 too long to conclude direct links between the two countries. Nevertheless, the new samples from
173 South-Ubangi cluster in the same subgroup (group II) according to previous classification of
174 MPXV sequences in clade Ia (14).

175 The PNLMPX-VHF investigated a further 109 suspected mpox cases from 15 health zones in
176 South Ubangi province from January to November 2023. Cases were predominantly male (60
177 males; 46 females; 3 unavailable) with an average age of 21 years (range 35 months to 63 years).
178 Of these, 61 cases (56 %) were confirmed positive by PCR at INRB. Three mpox negative cases
179 were confirmed positive for varicella zoster virus (3/48; 6%).

180

181 **DISCUSSION**

182 This investigation describes two clusters of mpox cases in Mbaya health zone in South Ubangi
183 province, DRC, presumably resulting from two different introductions. Epidemiological links to
184 cross-border travel from CAR were found in the first cluster and genomic links with previous
185 cases from CAR for both. MPXV transmission in DRC is currently driven by both zoonotic and
186 human to human contact, thus increasing the complexity of containment and mitigation efforts.
187 There are considerable concerns about wider regional and international expansion of mpox
188 including the concentration of MPXV outbreaks in CAR and DRC along the Ubangi River,
189 recent increases in sustained human-to-human transmission, resource limitations for
190 identification and treatment of mpox, disease stigma, population displacement due to conflict,
191 and transient cross-border transit.

192 In August 2022, a first regional meeting involving six neighbouring countries of Central and
193 West Africa was held in Kinshasa, DRC to establish a regional mpox surveillance network - the
194 Mpox Threat Reduction Network. Through this network multiple teams that included experts
195 from the Health Ministries of the DRC and CAR which were able to communicate rapidly on
196 suspected cases crossing borders in South Ubangi while also reporting to the International Health
197 Regulations focal point in the DRC and CAR. This investigation highlights the importance of
198 long-term collaborative partnerships for sustained mpox surveillance and containment in
199 endemic regions.

200

201

202

203

204

205

206

207

208

209

210

211

212

213

214

215

216

217

218

219

220 **ACKNOWLEDGEMENTS**

221 Figures included in this manuscript were generated using Biorender.com.

222

223 **FUNDING**

224 The project or effort depicted is sponsored by the Department of Defense Threat Reduction
225 Agency. The content of the information does not necessarily reflect the position or the policy of
226 the federal government, and no official endorsement should be inferred.

227 This work was also supported by the International Mpox Research Consortium (IMReC)
228 through funding from the Canadian Institutes of Health Research and International Development
229 Research Centre (Grant No. 202209MRR-489062-MPX-CDAA-168421) and the Agence
230 Française de Développement through the PANAFPOX and AFROSCREEN project (grant
231 agreement CZZ3209), coordinated by ANRS Maladies infectieuses émergentes in partnership
232 with Institut de Recherche pour le Développement (IRD). E.L. received a PhD grant from the
233 French Foreign Office.

234

235 **REFERENCES:**

- 236 1. Ladnyj ID, Ziegler P, Kima E. A human infection caused by monkeypox virus in
237 Basankusu Territory, Democratic Republic of the Congo. *Bull World Health Organ.*
238 1972;46(5):593-7.
- 239 2. Titanji BK, Tegomoh B, Nematollahi S, Konomos M, Kulkarni PA. Monkeypox: A
240 Contemporary Review for Healthcare Professionals. *Open Forum Infect Dis.* 2022
241 Jul;9(7):ofac310.
- 242 3. Happi C, Adetifa I, Mbala P, Njouom R, Nakoune E, Happi A, et al. Urgent need for a
243 non-discriminatory and non-stigmatizing nomenclature for monkeypox virus. *PLoS Biol.* 2022
244 Aug;20(8):e3001769.
- 245 4. Vakaniaki EH, Kacita C, Kinganda-Lusamaki E, O'Toole A, Wawina-Bokalanga T,
246 Mukadi-Bamuleka D, et al. Sustained Human Outbreak of a New MPXV Clade I Lineage in the
247 Eastern Democratic Republic of the Congo. *Nat Med.* 2024 Jun 13.
- 248 5. Weaver JR, Isaacs SN. Monkeypox virus and insights into its immunomodulatory
249 proteins. *Immunol Rev.* 2008 Oct;225:96-113.
- 250 6. McCollum AM, Damon IK. Human monkeypox. *Clin Infect Dis.* 2014 Jan;58(2):260-7.

- 251 7. Kibungu EM, Vakaniaki EH, Kinganda-Lusamaki E, Kalonji-Mukendi T, Pukuta E, Hoff
252 NA, et al. Clade I-Associated Mpox Cases Associated with Sexual Contact, the Democratic
253 Republic of the Congo. *Emerg Infect Dis*. 2024 Jan;30(1):172-6.
- 254 8. MSPHP. REPORT ON THE EPIDEMIOLOGICAL SITUATION OF MONKEYPOX
255 VIRUS—S1-S6 2024. Ministry of Public Health, Hygiene and Prevention of the Democratic
256 Republic of the Congo; 2024.
- 257 9. WHO. Disease Outbreak News: Mpox - Democratic Republic of the Congo; 2024 14
258 June 2024.
- 259 10. Mbala-Kingebeni P, Rimoin AW, Kacita C, Liesenborghs L, Nachega JB, Kindrachuk J.
260 The time is now (again) for mpox containment and elimination in Democratic Republic of the
261 Congo. *PLOS Glob Public Health*. 2024;4(6):e0003171.
- 262 11. Besombes C, Mbrenge F, Schaeffer L, Malaka C, Gonofio E, Landier J, et al. National
263 Monkeypox Surveillance, Central African Republic, 2001-2021. *Emerg Infect Dis*. 2022
264 Dec;28(12):2435-45.
- 265 12. Kalyanamoorthy S, Minh BQ, Wong TKF, von Haeseler A, Jermin LS. ModelFinder:
266 fast model selection for accurate phylogenetic estimates. *Nat Methods*. 2017 Jun;14(6):587-9.
- 267 13. Minh BQ, Schmidt HA, Chernomor O, Schrempf D, Woodhams MD, von Haeseler A, et
268 al. IQ-TREE 2: New Models and Efficient Methods for Phylogenetic Inference in the Genomic
269 Era. *Mol Biol Evol*. 2020 May 1;37(5):1530-4.
- 270 14. Berthet N, Descorps-Declere S, Besombes C, Curaudeau M, Nkili Meyong AA, Selekon
271 B, et al. Genomic history of human monkey pox infections in the Central African Republic
272 between 2001 and 2018. *Sci Rep*. 2021 Jun 22;11(1):13085.

273

274

275

276

277

278

279

280

281


282

283

284


285

286
287
288
289
290
291
292
293
294
295
296
297
298
299
300
301
302
303




304 **Figure 1.** Suggested transmission route of MPXV between Bangui, Central African Republic
305 (CAR) and Mbaya Health Zone, South Ubangi Province, Democratic Republic of the Congo,
306 January 2023

307
308
309
310
311
312
313
314
315
316
317
318



319
320
321
322
323
324
325
326
327
328
329
330
331
332
333
334
335
336
337
338
339

Figure 2. Suggested transmission chain from Central African Republic to the Democratic Republic of the Congo and second identified chain at Mbaya General Reference Hospital, DRC. Abbreviations: HCW, healthcare workers; HZ, health zone



340
341

342 **Figure 3: Phylogenetic analysis of MPXV sequences from Mbaya rural health zone.**
 343 Phylogenetic analysis of MPXV genome sequences from samples described in this study and
 344 clade I MPXV sequences from Central Africa. Scale bar is in substitutions per site; bootstrap
 345 support values are shown at branch points. DNA was extracted at INRB using a Qiagen DNA
 346 Mini kit from blood samples and subsequently screened for MPXV with an Orthopoxvirus-
 347 specific real-time PCR assay. Whole genome sequencing was attempted on samples from the
 348 index case by Next Generation Sequencing (NGS). The library preparation was performed using
 349 Illumina DNA Prep with Enrichment and the libraries were enriched for MPXV using
 350 biotinylated custom probes synthesized by Twist Biosciences. Note that 23MPX0134C(D2),

351 23MPX0135V(C2), and 23MPX0136V(C3) are samples from crust or vesicles from separate
352 individuals.